Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04245553
Other study ID # 6028481
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 7, 2020
Est. completion date March 1, 2021

Study information

Verified date April 2024
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Paracentesis is a bedside procedure in which a needle is inserted into a patient's peritoneum in order to obtain ascitic fluid. This is a safe bedside procedure with very low risks of complications that is usually performed using physical exam maneuvers to determine the site of needle insertion. Point of care ultrasound (POCUS) technology has improved the safety of central venous catheter insertion and thoracentesis, yet the data on safety in paracentesis is equivocal. In a practical study, we aim to determine if POCUS will change the needle insertion site over the traditional anatomic landmarking method. Operators will landmark for paracentesis using conventional physical exam and then utilize POCUS to determine if there is a more optimal site. The primary endpoint will be whether POCUS yielded a change in the needle insertion site, as defined by a location greater than 5cm from the anatomic site, at least 20% of the time. The results will further our understanding of POCUS in improving procedural safety, thereby adding to the currently limited literature on this topic. Furthermore, this study will inform residency training programs about the utility in POCUS training for paracentesis and may advocate for the availability of POCUS devices to physicians performing this procedure.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date March 1, 2021
Est. primary completion date March 1, 2021
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility This is in effort to capture routine paracentesis cases. Inclusion Criteria: - Participants scheduled to have either a diagnostic of therapeutic paracentesis. - Participants can be either inpatients under the care of general internal medicine, or outpatients under the care of gastroenterology or general internal medicine. - Operators will be recruited on a volunteer basis and will include medical residents or subspecialty fellows with knowledge of POCUS for paracentesis purposes, either through core residency programs or more advanced training. Exclusion Criteria: - Loculated ascites - Current anticoagulation - Hemodynamic instability - Bowel obstruction - Pregnancy - Abdominal wall cellulitis - Platelet count <20

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Abdominal Point of Care Ultrasound
Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.

Locations

Country Name City State
Canada Kingston Health Sciences Center Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Steven Montague

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Preference of land-marking method Does the clinician performing the procedure prefer the needle insertion site found using point of care ultrasound, or using the traditional anatomic method. A clinically significant difference in location is defined as greater than or equal to 5cm apart. If the difference in locations is not at least 5cm apart, this will be defined as no preference in land-marking methods. Determined immediatly after the POCUS landmarking is done.
Secondary Depth of Ascitis Depth of ascitis, measured perpendicular to the overlying skin, at the location land-marked using traditional anatomic method, versus the location found with point of care ultrasound. Determined immediatly after the POCUS landmarking is done.
Secondary Immediate Complications The overall rate of any complications observed while performing the procedure. This includes bleeding, perforation/puncture of any internal organ, or a failed attempt. Occuring at any time between the needle insertion and removal of the paracentesis drain.
See also
  Status Clinical Trial Phase
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting NCT00239096 - Prevention of Decompensation in Liver Cirrhosis Phase 4
Active, not recruiting NCT03973866 - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) N/A
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Terminated NCT01455246 - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Completed NCT01578226 - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis N/A
Terminated NCT00548366 - Sodium Restriction in the Management of Cirrhotic Ascites Phase 4
Recruiting NCT05025878 - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A
Not yet recruiting NCT04550091 - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4
Completed NCT01769040 - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis Phase 4
Recruiting NCT05511766 - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Phase 2/Phase 3
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed NCT03263598 - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed NCT00907673 - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure N/A
Terminated NCT00796861 - Trial of Sunitinib for Refractory Malignant Ascites Phase 2
Suspended NCT00511394 - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis N/A